Dysequilibrium DRG Reimbursement & Medicare Rates

Summary & Overview

Dysequilibrium: Inpatient Reimbursement Overview

DRG 149 addresses inpatient stays for dysequilibrium, encompassing balance disorders and gait instability that require acute evaluation and management. It matters for inpatient reimbursement because assignment to this Diagnosis-Related Group defines the bundled Medicare payment based on expected resource use for diagnosis, observation, and short-term treatment.

DysequilibriumDRG DysequilibriumDRG 149Diagnosis-Related GroupInpatient ReimbursementMedicareNeurologyGeriatricsPhysical TherapyFall Prevention

DRG 149 Overview

DRG 149 covers inpatient stays primarily for dysequilibrium, a clinical syndrome of impaired balance that can lead to falls, syncope-like episodes, or gait instability requiring evaluation and management. This Diagnosis-Related Group matters for Medicare payment because it groups patients with similar resource needs for acute diagnostic workup, observation, and potential physical therapy evaluation into a single payment category. Accurate clinical documentation and coding determine assignment to this DRG and thus influence hospital reimbursement and quality reporting. The grouping reflects typical resource use for short inpatient stays focused on assessment, stabilization, and discharge planning.

National Payment Rates

Across commercial payers the observed rate range spans from about $370 to $26K, with mean payer payments clustering between roughly $7K and $12K. The widest spread appears between BCBS (min ~$370, max $20K) and Anthem (min ~$390, max $26K), indicating substantial variability across contracts. See the table and chart below for payer-specific quartiles and ranges.

Mean Rates by Payer — National — DRG 149

The CMS 2023 data represent national Medicare fee-for-service inpatient payments reported under the CMS Provider Utilization and Payment Data program. The table below shows average total payment ($7.2k), average submitted covered charges ($41.3k), average Medicare payment ($5.2k), and total discharges (13.9k).

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

Alaska’s DRG 149 reimbursement cluster spans roughly $12K to $18K across reported payers, with Anthem and Blue Cross Blue Shield both fixed near $12K and Cigna notably higher around $18K. The most notable deviation from national averages is Cigna’s elevated median in Alaska relative to several national payer medians. See the table and chart below for detailed percentile values.

Key Insights for Alaska

Highest payer: Cigna (~$18K median) is the top-paying insurer in Alaska; Lowest payers: Anthem and BCBS are both flat at ~$12K across percentiles.
Alaska’s payers show a narrow clustered range for Anthem and BCBS at ~$12K, while Cigna is meaningfully higher than those local benchmarks and above typical national medians for some payers.

Clinical Trials

Acute vestibular rehabilitation and early in-hospital balance intervention trials: randomized or controlled pilot studies evaluating structured, early vestibular physiotherapy or multisensory balance training initiated during the inpatient stay for patients admitted with acute dysequilibrium (often older adults with falls, new-onset vertigo, or vestibular hypofunction). These studies target short-term outcomes such as in-hospital fall rates, length of stay, and improvement on objective balance measures (e.g., gait speed, Timed Up and Go), and are relevant because effective in-hospital interventions may reduce complications and downstream costs for high-risk patients. Payers and providers benefit from evidence about which acute therapies shorten LOS or reduce readmissions and fall-related costs.
Comparative diagnostic strategy and etiology-focused effectiveness studies: prospective cohort or pragmatic trials comparing diagnostic pathways (for example, enhanced vestibular testing and multidisciplinary evaluation versus standard care) to identify causes of dysequilibrium in heterogeneous inpatient populations including stroke, orthostatic hypotension, peripheral vestibular disorders, and medication-induced imbalance. These studies examine diagnostic yield, time to definitive diagnosis, treatment targeting, and resource utilization, addressing the clinical question of how best to triage and manage complex causes of imbalance in medically ill patients. Results inform providers about efficient workups and help payers assess the value of advanced diagnostics in reducing unnecessary imaging, consultations, or prolonged admissions.
Post-discharge outcomes and transitional care interventions: longitudinal trials and cohort studies of discharge planning, home-based balance rehabilitation, tele-rehabilitation, or fall prevention programs for patients hospitalized with dysequilibrium, typically older adults with comorbidities and functional impairment. Research focuses on 30- to 90-day outcomes such as falls, emergency visits, rehospitalization, functional status, and durable improvements in mobility, providing evidence about which transitional care models lower downstream morbidity and costs. This area is crucial to payers and health systems because preventing post-discharge falls and readmissions directly impacts total cost of care and quality metrics for this DRG.

Other Ear, Nose, Mouth and Throat Diagnoses without CC/MCC: Inpatient Reimbursement Overview

148-EAR-NOSE-MOUTH-AND-THROAT-MALIGNANCY-WITHOUT-CC-MCC

Ear, Nose, Mouth and Throat Malignancy without CC/MCC: Inpatient Reimbursement Overview

140-MAJOR-HEAD-AND-NECK-PROCEDURES-WITH-MCC

Major Head and Neck Procedures with MCC: Inpatient Reimbursement Overview

146-EAR-NOSE-MOUTH-AND-THROAT-MALIGNANCY-WITH-MCC

Ear, Nose, Mouth and Throat Malignancy with MCC: Inpatient Reimbursement Overview

141-MAJOR-HEAD-AND-NECK-PROCEDURES-WITH-CC

Major Head and Neck Procedures with CC: Inpatient Reimbursement Overview

138-MOUTH-PROCEDURES-WITHOUT-CC-MCC

Mouth Procedures without CC/MCC: Inpatient Reimbursement Overview

147-EAR-NOSE-MOUTH-AND-THROAT-MALIGNANCY-WITH-CC

Ear, Nose, Mouth and Throat Malignancy with CC: Inpatient Reimbursement Overview

135-SINUS-AND-MASTOID-PROCEDURES-WITH-CC-MCC

Sinus and Mastoid Procedures with CC/MCC: Inpatient Reimbursement Overview

154-OTHER-EAR-NOSE-MOUTH-AND-THROAT-DIAGNOSES-WITH-MCC

Other Ear, Nose, Mouth and Throat Diagnoses with MCC: Inpatient Reimbursement Overview

136-SINUS-AND-MASTOID-PROCEDURES-WITHOUT-CC-MCC

Sinus and Mastoid Procedures without CC/MCC: Inpatient Reimbursement Overview

Showing 1–10 of 24

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Average Total Payment	Average Submitted Charges	Average Medicare Payment	Total Discharges
$7.2K	$41K	$5.2K	14K